At Mediq, the safety and security of our products and services is of the utmost importance, and we greatly value the privacy of our customer. Securing the safety of our IT-systems is a top priority. Despite all of the care and attention for the security of the systems it can happen that (temporarily) a vulnerability is overlooked.
If you believe to have discovered a vulnerability, we would like to be informed about this so we can take steps to address this as quickly as possible. We would like to cooperate with you to help us better protect our clients data and our systems. To prevent misuse of any potential vulnerability by others, we ask you to follow the following guidelines when you notify us:
• E-mail your findings to email@example.com. When possible, encrypt your findings using our PGP key to prevent this critical information from falling into the wrong hands.
• Provide sufficient information to reproduce the detected vulnerability, so we will be able to resolve it as quickly as possible. Usually, the IP address or the URL of the affected system and a description of the vulnerability will be sufficient, but complex vulnerabilities may require further explanation.
• Do not take advantage of the vulnerability you have discovered, for example by downloading more data than necessary to demonstrate the vulnerability or deleting or modifying other people's data,
• Do not reveal the vulnerability to others and delete all confidential data obtained.
• Provide your contact details so that Mediq can contact you to work together on fixing the issue. Provide at the minimum your email address or telephone number.
• Place malware on our systems.
• Copy, change or delete data in a system (an alternative for this is making a directory listing of a system).
• Make changes to the system.
• Access the system repeatedly or sharing access with others.
• Use so called ‘brute force attacks’ to access systems.
• Use denial-of-service or social engineering.
The policy for responsible disclosure is not an invitation to actively scan our IT systems for vulnerabilities. Mediq scans and monitors its IT systems itself.
• We will respond to your report within 3 business days with our evaluation of the report and an expected resolution date.
• If you have followed the instructions above, we will not take any legal action against you regarding how you gained access, the breach and the reporting of the vulnerability.
• We will handle your report with strict confidentiality, and will not pass on your personal details to third parties without your permission, unless required to comply with the law. It is possible report vulnerabilities anonymous.
• We will keep you informed on the progress towards resolving the vulnerability.
• Mediq will provide full credit to researchers who make a vulnerability report or perform testing, in publicly released patch or security fix release information, if requested.
• comments on the services that Mediq provides
• comments or questions about the accessibility of our services
• reporting fraud or potential fraud
• reporting potential false or so-called phishing e-mails
• reporting viruses and / or malware
• reporting of complaints
E. Thyssen (1961), Belgian nationality
• Present term expires in 2023
• Current position: Managing Director of Alpinvest Partners
P.H.J.M. Visée (1961), Dutch nationality
• Present term expires in 2023
• Current position: Supervisory board member at Rabobank, Plus Retail BV en Royal Flora Holland
• Other positions: Lid raad van toezicht Erasmus Universiteit, bestuurslid Stichting Albron, senior adviseur (extern) Genpact Inc., senior adviseur (extern) McKinsey & Company Inc., voorzitter raad van toezicht Stedelijk Museum Schiedam, bestuurslid Prins Claus Fond
T.A. Allen, British nationality
• Present term expires in 2023
• Current position: Managing Director at Advent International
• Other positions: Non-executive director of Syneos Health Inc. and Zentiva Group a.s.
J.D.S. Woollard, Britse nationaliteit
• Present time expires in 2023
• Current position: Assistant Director at Advent International
Responsibilities of the Supervisory Board
The Supervisory Board supervises the policy of the Board of Management and the general affairs of the company. Mediq is subject to the full, mitigated two-tier board regime. In terms of governance, this means mainly that the • Supervisory Board is not only responsible for exercising supervision, but also for dismissing members of the Board of Management, for nominating members of the Supervisory Board, and for approving various decisions of the Board of Management.
The duties of the Supervisory Board, which are described in the Regulations of the Supervisory Board, include:
•supervising and monitoring (in advance or otherwise), and advising the Board of Management on:
• (i) the achievement of the company's aims,
• (ii) the company's strategy and the risks inherent in its business activities,
• (iii) the structure and management of the internal risk management and control systems,
• (iv) the financial reporting process and
• (v) compliance with legislation and regulations;
• disclosing, complying with and enforcing the company's corporate governance structure;
• approving annual budgets and the company's major capital investments;
• selecting and recommending the appointment of the company's external auditor;
• selecting members of the Board of Management, proposing the remuneration policy for members of the Board of Management, for approval bythe general shareholders’ meeting of the company, fixing the remuneration in accordance with the said remuneration policy and contractual terms and conditions of employment of members of the Board of Management;
• selecting and recommending the appointment of members of the Supervisory Board, and proposing the remuneration of its members, for approval by the general shareholders’ meeting;
• evaluating and assessing the functioning of the Board of Management, the Supervisory Board, and their individual members (including theevaluation of the Supervisory Board profile and the induction, education and training program);
• dealing with, and deciding on, reported potential conflicts of interests between the company on the one side and members of the Board of Management, the external auditor and the major shareholder(s) on the other side;
• dealing with, and deciding on, reported alleged irregularities that relate to the functioning of Board of Management members.
Members of the Supervisory Board are appointed by the Annual General Meeting of Shareholders. The nominees must fit within the profile of the Supervisory Board. The Central Works Council can make a recommendation. Members of the Supervisory Board resign according to a periodic retirement schedule set by the Supervisory Board. They step down at the first General Meeting of Shareholders following the end of their four-year term of office.
The Supervisory Board has set up three committees drawn from its members for the selection and appointment of members of the Board of Management and Supervisory Board (Selection & Appointment Committee), remuneration (Remuneration Committee) and reporting and risk management (Audit Committee). The function of the committees is to prepare the way for decision-making by the Supervisory Board in these areas. Decisions are always taken by the full board.
Per 1 April 2017 Christian Wojczewski was appointed Chief Executive Officer of Mediq."Improving quality of life by helping people to participate in society for as long as possible: that is what it is all about."
Paul Hitchin was appointed CFO of Mediq on 1 January 2018.
"Affordable healthcare means continuously striving to find new efficiencies and a relentless approach to continuous innovation and improvement."
Paul Hitchin has extensive international experience in financial leadership functions. He is a British national and joined Ford Motor Company in 2001 where he worked in finance. Since 2004, he has held global CFO positions at General Electric, amongst others in the healthcare industry as CFO of GE Biotechnologies and most recently as global CFO of General Electric Mining.
Paul is married and has two children.
In July 2015 Alex Jonker was appointed as Executive Vice President Supply Chain. And on 1 October Alex Jonker became EVP Sourcing.
"Our challenge is to raise the supply chain of Mediq to the best in class. The key areas of result will be supply chain efficiency and customer service performance.”
In his last role, Alex Jonker was Supply Chain and E-commerce Director and a member of the board of directors at HEMA. Jonker has spent the majority of his career at HEMA and has over 20 years' experience in retail Supply Chain Management on a European scale.
Alex is married and has two children.
Leah Bayer was appointed Executive Vice President DACH on 1 January 2020. Before this appointment Leah Bayer worked as EVP Sourcing at Mediq.
"In the current dynamics of the international healthcare market, it is important that Mediq focuses on a good balance between improving the care of patients and keeping care affordable."
Before joining Mediq, Leah Bayer was Vice President Clinical and Strategy EMEA at Davita. Bayer has held various managerial and advisory positions with firms including Bain & Company, and PwC Consulting, and holds an MBA from the Tuck School of Business at Dartmouth.
Leah Bayer is American by origin and born in Colorado, USA.
As of 1 September 2014 Stefaan Kindekens (1968) is CIO within Mediq.
"We want to give patients and care professionals access to Mediq through as many channels as possible, by using technology in the most efficient way."
At his last role, Stefaan was CIO at a Belgian multinational Electronica organization (Barco). Prior to that Stefaan worked for KPMG, Coca-Cola en Procter & Gamble.
Stefaan has the Belgian nationality and has three children.
Eveline de Wit joined Mediq as CHRO in 2018, most recently she worked for Thermo Fisher Scientific as VP of HR for their pharma division, Patheon. Prior to this she worked for Univar, GE Capital and Heineken. Eveline holds a masters degree in business administration from the University of Nijmegen and a bachelors degree in hotel management from the University of Maastricht.
"It’s about the people at Mediq. Together, we improve the lives of patients and families by living our values. Caring Heart, Customer Drive and Champion Spirit."
Christian Kanstrup was appointed EVP Nordics and Baltics on 14 May 2019.
“I want to develop a world-class organization in the Nordics and Baltics being able to bring all relevant stakeholders in the healthcare community together thereby creating even better lives for the many people with chronic diseases as well as all the other people we serve every day”.
Christian worked for Novo Nordisk for the last 20 years, most recently as Senior Vice President & Head of Biopharm Operations. Starting his career in finance, he expanded in investor relations, moving on to a broad range of general management and strategy leadership roles in the Nordics, USA, Asia and Switzerland.
Christian holds a Masters in Economics (cand.polit.) from University of Copenhagen as well as post graduate training from IMD. Christian among other things also serves on the board of the Copenhagen NASDAQ listed NNIT as well as the private biotechnology company Glycom.
Christian is married and has two children.